바이오의약품 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of biopharmaceuticals Market

The global biopharmaceuticals market continues to expand steadily, supported by rising chronic disease prevalence, increasing geriatric population, and strong innovation in biologics and advanced therapies. The market was valued at USD 666.41 billion in 2025 and is projected to grow from USD 720.72 billion in 2026 to USD 1,411.48 billion by 2034, registering a CAGR of 8.6% during 2026-2034.

In 2025, North America dominated the global market with a 50.37% share, driven by strong reimbursement systems, high diagnosis rates, and rapid adoption of advanced biologics.

Biopharmaceuticals are complex medicines derived from biological sources using biotechnology. These include proteins, monoclonal antibodies, nucleic acids, vaccines, hormones, and cell and gene therapies. Growing aging populations and the rising burden of chronic diseases are significantly increasing global demand.

COVID-19 Impact

The market experienced strong positive growth during the COVID-19 pandemic. The rapid development, approval, and global distribution of COVID-19 vaccines and therapeutics significantly boosted revenues in 2021. Regulatory flexibility and emergency approvals accelerated product launches.

From 2023 onward, as COVID-19 cases declined, the market transitioned toward steady growth driven by robust pipeline candidates and increasing approvals across oncology, immunology, and rare diseases.

Market Trends

Strong Pipeline Development in Emerging Regions

Asia Pacific has emerged as a clinical trial hub, accounting for nearly 50% of global clinical activity (Cytel, 2023). China alone contributes nearly 40% of Phase I trials in the region. Increasing licensing of early-stage cancer therapies from Chinese biotech firms to global pharmaceutical companies is a key trend.

The number of CAR-T therapy pipeline candidates has surged significantly. In March 2023, 443 CAR-T pipeline candidates were listed on ClinicalTrials.gov, compared to only 12 in 2012. Growing regulatory approvals for advanced therapies are reshaping the competitive landscape.

Market Growth Drivers

Rising Prevalence of Chronic Diseases

Chronic diseases are a major global health burden. According to WHO (2023), 41 million deaths annually are attributed to non-communicable diseases, accounting for 74% of global deaths. Rising diagnosis rates and awareness programs are increasing demand for innovative biologics.

Increasing Approvals for Monoclonal Antibodies

Monoclonal antibodies remain a major growth driver. Between 2020 and 2021, regulatory agencies approved 97 monoclonal antibodies, along with gene therapies, hormones, and vaccines. Accelerated approvals for oncology and autoimmune treatments continue to fuel market expansion.

Restraining Factors

High Drug Development and Treatment Costs

Biopharmaceutical development is capital-intensive. WHO (2022) estimates the cost of developing a new drug ranges between USD 43.4 million and USD 4.2 billion.

Additionally, advanced therapies such as CAR-T treatments are highly expensive. For example, one treatment cycle of CAR-T therapy can cost approximately USD 475,000. High pricing may limit accessibility and slow adoption in certain regions.

Market Segmentation Analysis

By Type

The market is segmented into immunomodulators, vaccines, hormones, enzymes, and others.

• Immunomodulators dominated in 2024 and are projected to hold 54.01% share in 2026, driven by monoclonal antibody approvals and cytokine therapies.
• Vaccines held the second-largest share in 2024, supported by routine immunization programs and new vaccine approvals.
• The hormone segment growth is driven by rising diabetes prevalence. In 2023, 537 million people were living with diabetes globally.
• Enzymes and anti-infectives contribute steady but comparatively moderate growth.

By Application

Applications include oncology, cardiology, respiratory, immunology, neurology, and others.

• Oncology dominated the market in 2024 and is projected to account for 45.3% share in 2026. Rising cancer incidence is a primary factor.
• The respiratory segment held the second-largest share.
• Immunology is expected to grow at the second-highest CAGR due to pipeline approvals for autoimmune diseases.
• Neurology and cardiology show moderate but steady growth.

By Distribution Channel

Segments include hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

• Hospital pharmacies dominated in 2024 due to inpatient administration of advanced biologics.
• Drug stores & retail pharmacies are projected to contribute 35.87% share in 2026.
• Online pharmacies are expected to grow at the highest CAGR due to digital adoption and doorstep delivery services.

Regional Insights

North America

North America generated USD 335.65 billion in 2025, maintaining its leadership. The U.S. market is projected to reach USD 345.8 billion by 2026. Strong reimbursement frameworks and high oncology drug adoption drive regional growth.

Europe

Europe holds a substantial market share. The UK market is projected to reach USD 30.55 billion by 2026, while Germany is expected to reach USD 48.16 billion by 2026. Government funding and strategic partnerships support expansion.

Asia Pacific

Asia Pacific is projected to grow at the highest CAGR. By 2026:

• Japan: USD 17.34 billion
• China: USD 41.07 billion
• India: USD 7.96 billion

Rising clinical trials, regulatory approvals, and growing patient awareness fuel regional growth.

Rest of the World

Latin America and the Middle East & Africa are expected to grow at a comparatively lower CAGR due to infrastructure limitations but improving healthcare systems are gradually supporting expansion.

Key Industry Players

Leading companies shaping the global market include:

• Pfizer Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Bayer AG
• Eli Lilly
• Sanofi
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited

Pfizer Inc. dominated the market during the COVID-19 period due to strong vaccine sales performance.

Conclusion

The global biopharmaceuticals market is projected to expand from USD 666.41 billion in 2025 to USD 1,411.48 billion by 2034, growing at a CAGR of 8.6% during 2026-2034. Rising chronic disease prevalence, increasing monoclonal antibody approvals, and robust pipeline development-particularly in oncology and immunology-are key growth drivers. While high development and treatment costs remain a challenge, expanding clinical research, technological innovation, and strong regional investments, especially in North America and Asia Pacific, are expected to sustain long-term market growth.

Segmentation By Type

• Immunomodulators
  • Monoclonal Antibodies
  • Cytokines
  • Interferons
  • Others
• Enzymes
  • Hyrdolases
  • Lyases
  • Oxidoreductases
  • Others
• Vaccines
  • Recombinant/Conjugate/Subunit
  • Inactivated
  • Live Attenuated
  • Toxoid
• Hormones
  • Human Growth Hormones
  • Insulin
  • Thyroid Stimulating Hormones
  • Others
• Others

By Application

• Cardiology
• Oncology
• Respiratory
• Immunology
• Neurology
• Others

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Type, Application, Distribution Channel, and Country)
  • U.S. (By Application)
  • Canada (By Application)
• Europe (By Type, Application, Distribution Channel, Country, and Country/Sub-Region)
  • U.K. (By Application)
  • Germany (By Application)
  • France (By Application)
  • Italy (By Application)
  • Spain (By Application)
  • Scandinavia (By Application)
  • Rest of Europe (By Application)
• Asia Pacific (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • China (By Application)
  • India (By Application)
  • Japan (By Application)
  • Australia (By Application)
  • Southeast Asia (By Application)
  • Rest of Asia Pacific (By Application)
• Latin America (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • Brazil (By Application)
  • Mexico (By Application)
  • Rest of Latin America (By Application)
• Middle East & Africa (By Type, Application, Distribution Channel, and Country/Sub-Region)
  • GCC (By Application)
  • South Africa (By Application)
• Rest of Middle East & Africa (By Application)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.4. Regulatory Scenario, By Key Countries/Regions
• 4.5. Pipeline Analysis, By Key Players
• 4.6. Impact of COVID-19 on the Market

5. Global Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Immunomodulators
    • 5.1.1.1. Monoclonal Antibodies
    • 5.1.1.2. Cytokines
    • 5.1.1.3. Interferons
    • 5.1.1.4. Others
  • 5.1.2. Enzymes
    • 5.1.2.1. Hyrdolases
    • 5.1.2.2. Lyases
    • 5.1.2.3. Oxidoreductases
    • 5.1.2.4. Others
  • 5.1.3. Vaccines
    • 5.1.3.1. Recombinant/Conjugate/Subunit
    • 5.1.3.2. Inactivated
    • 5.1.3.3. Live Attenuated
    • 5.1.3.4. Toxoid
  • 5.1.4. Hormones
    • 5.1.4.1. Human Growth Hormones
    • 5.1.4.2. Insulin
    • 5.1.4.3. Thyroid Stimulating Hormones
    • 5.1.4.4. Others
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Cardiology
  • 5.2.2. Oncology
  • 5.2.3. Respiratory
  • 5.2.4. Immunology
  • 5.2.5. Neurology
  • 5.2.6. Others
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Hospital Pharmacies
  • 5.3.2. Drug Stores & Retail Pharmacies
  • 5.3.3. Online Pharmacies
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Immunomodulators
    • 6.1.1.1. Monoclonal Antibodies
    • 6.1.1.2. Cytokines
    • 6.1.1.3. Interferons
    • 6.1.1.4. Others
  • 6.1.2. Enzymes
    • 6.1.2.1. Hyrdolases
    • 6.1.2.2. Lyases
    • 6.1.2.3. Oxidoreductases
    • 6.1.2.4. Others
  • 6.1.3. Vaccines
    • 6.1.3.1. Recombinant/Conjugate/Subunit
    • 6.1.3.2. Inactivated
    • 6.1.3.3. Live Attenuated
    • 6.1.3.4. Toxoid
  • 6.1.4. Hormones
    • 6.1.4.1. Human Growth Hormones
    • 6.1.4.2. Insulin
    • 6.1.4.3. Thyroid Stimulating Hormones
    • 6.1.4.4. Others
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Cardiology
  • 6.2.2. Oncology
  • 6.2.3. Respiratory
  • 6.2.4. Immunology
  • 6.2.5. Neurology
  • 6.2.6. Others
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Hospital Pharmacies
  • 6.3.2. Drug Stores & Retail Pharmacies
  • 6.3.3. Online Pharmacies
  • 6.3.4. Other Facilities
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
    • 6.4.1.1. By Application
  • 6.4.2. Canada
    • 6.4.2.1. By Application

7. Europe Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Immunomodulators
    • 7.1.1.1. Monoclonal Antibodies
    • 7.1.1.2. Cytokines
    • 7.1.1.3. Interferons
    • 7.1.1.4. Others
  • 7.1.2. Enzymes
    • 7.1.2.1. Hyrdolases
    • 7.1.2.2. Lyases
    • 7.1.2.3. Oxidoreductases
    • 7.1.2.4. Others
  • 7.1.3. Vaccines
    • 7.1.3.1. Recombinant/Conjugate/Subunit
    • 7.1.3.2. Inactivated
    • 7.1.3.3. Live Attenuated
    • 7.1.3.4. Toxoid
  • 7.1.4. Hormones
    • 7.1.4.1. Human Growth Hormones
    • 7.1.4.2. Insulin
    • 7.1.4.3. Thyroid Stimulating Hormones
    • 7.1.4.4. Others
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Cardiology
  • 7.2.2. Oncology
  • 7.2.3. Respiratory
  • 7.2.4. Immunology
  • 7.2.5. Neurology
  • 7.2.6. Others
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Hospital Pharmacies
  • 7.3.2. Drug Stores & Retail Pharmacies
  • 7.3.3. Online Pharmacies
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. U.K.
    • 7.4.1.1. By Application
  • 7.4.2. Germany
    • 7.4.2.1. By Application
  • 7.4.3. France
    • 7.4.3.1. By Application
  • 7.4.4. Italy
    • 7.4.4.1. By Application
  • 7.4.5. Spain
    • 7.4.5.1. By Application
  • 7.4.6. Scandinavia
    • 7.4.6.1. By Application
  • 7.4.7. Rest of Europe
    • 7.4.7.1. By Application

8. Asia Pacific Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Immunomodulators
    • 8.1.1.1. Monoclonal Antibodies
    • 8.1.1.2. Cytokines
    • 8.1.1.3. Interferons
    • 8.1.1.4. Others
  • 8.1.2. Enzymes
    • 8.1.2.1. Hyrdolases
    • 8.1.2.2. Lyases
    • 8.1.2.3. Oxidoreductases
    • 8.1.2.4. Others
  • 8.1.3. Vaccines
    • 8.1.3.1. Recombinant/Conjugate/Subunit
    • 8.1.3.2. Inactivated
    • 8.1.3.3. Live Attenuated
    • 8.1.3.4. Toxoid
  • 8.1.4. Hormones
    • 8.1.4.1. Human Growth Hormones
    • 8.1.4.2. Insulin
    • 8.1.4.3. Thyroid Stimulating Hormones
    • 8.1.4.4. Others
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Cardiology
  • 8.2.2. Oncology
  • 8.2.3. Respiratory
  • 8.2.4. Immunology
  • 8.2.5. Neurology
  • 8.2.6. Others
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Hospital Pharmacies
  • 8.3.2. Drug Stores & Retail Pharmacies
  • 8.3.3. Online Pharmacies
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. China
    • 8.4.1.1. By Application
  • 8.4.2. India
    • 8.4.2.1. By Application
  • 8.4.3. Japan
    • 8.4.3.1. By Application
  • 8.4.4. Australia
    • 8.4.4.1. By Application
  • 8.4.5. Southeast Asia
    • 8.4.5.1. By Application
  • 8.4.6. Rest of Asia Pacific
    • 8.4.6.1. By Application

9. Latin America Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Immunomodulators
    • 9.1.1.1. Monoclonal Antibodies
    • 9.1.1.2. Cytokines
    • 9.1.1.3. Interferons
    • 9.1.1.4. Others
  • 9.1.2. Enzymes
    • 9.1.2.1. Hyrdolases
    • 9.1.2.2. Lyases
    • 9.1.2.3. Oxidoreductases
    • 9.1.2.4. Others
  • 9.1.3. Vaccines
    • 9.1.3.1. Recombinant/Conjugate/Subunit
    • 9.1.3.2. Inactivated
    • 9.1.3.3. Live Attenuated
    • 9.1.3.4. Toxoid
  • 9.1.4. Hormones
    • 9.1.4.1. Human Growth Hormones
    • 9.1.4.2. Insulin
    • 9.1.4.3. Thyroid Stimulating Hormones
    • 9.1.4.4. Others
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Cardiology
  • 9.2.2. Oncology
  • 9.2.3. Respiratory
  • 9.2.4. Immunology
  • 9.2.5. Neurology
  • 9.2.6. Others
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Drug Stores & Retail Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.4.1. Brazil
    • 9.4.1.1. By Application
  • 9.4.2. Mexico
    • 9.4.2.1. By Application
  • 9.4.3. Rest of Latin America
    • 9.4.3.1. By Application

10. Middle East & Africa Biopharmaceuticals Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Immunomodulators
    • 10.1.1.1. Monoclonal Antibodies
    • 10.1.1.2. Cytokines
    • 10.1.1.3. Interferons
    • 10.1.1.4. Others
  • 10.1.2. Enzymes
    • 10.1.2.1. Hyrdolases
    • 10.1.2.2. Lyases
    • 10.1.2.3. Oxidoreductases
    • 10.1.2.4. Others
  • 10.1.3. Vaccines
    • 10.1.3.1. Recombinant/Conjugate/Subunit
    • 10.1.3.2. Inactivated
    • 10.1.3.3. Live Attenuated
    • 10.1.3.4. Toxoid
      • 10.1.3.4.1. Hormones
        • 10.1.3.4.1.1. Human Growth Hormones
        • 10.1.3.4.1.2. Insulin
        • 10.1.3.4.1.3. Thyroid Stimulating Hormones
        • 10.1.3.4.1.4. Others
      • 10.1.3.4.2. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Cardiology
  • 10.2.2. Oncology
  • 10.2.3. Respiratory
  • 10.2.4. Immunology
  • 10.2.5. Neurology
  • 10.2.6. Others
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Drug Stores & Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.4.1. GCC
    • 10.4.1.1. By Application
  • 10.4.2. South Africa
    • 10.4.2.1. By Application
  • 10.4.3. Rest of Middle East & Africa
    • 10.4.3.1. By Application

11. Competitive Analysis

• 11.1. Global Market Share Analysis ( 2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. AbbVie Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Bristol-Myers Squibb Company
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Johnson & Johnson Services, Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Bayer AG
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Lilly
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Sanofi
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Merck & Co., Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. F. Hoffmann-La Roche Ltd
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)
  • 11.2.10. Novartis AG
    • 11.2.10.1. Overview
    • 11.2.10.2. Products & Services
    • 11.2.10.3. SWOT Analysis
    • 11.2.10.4. Recent Developments
    • 11.2.10.5. Strategies
    • 11.2.10.6. Financials (Based on Availability)
  • 11.2.11. GSK plc
    • 11.2.11.1. Overview
    • 11.2.11.2. Products & Services
    • 11.2.11.3. SWOT Analysis
    • 11.2.11.4. Recent Developments
    • 11.2.11.5. Strategies
    • 11.2.11.6. Financials (Based on Availability)
  • 11.2.12. Takeda Pharmaceutical Company Limited.
    • 11.2.12.1. Overview
    • 11.2.12.2. Products & Services
    • 11.2.12.3. SWOT Analysis
    • 11.2.12.4. Recent Developments
    • 11.2.12.5. Strategies
    • 11.2.12.6. Financials (Based on Availability)